These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 24581432)

  • 41. A 36-month study on the cost/utility of add-on omalizumab in persistent difficult-to-treat atopic asthma in Italy.
    Dal Negro RW; Tognella S; Pradelli L
    J Asthma; 2012 Oct; 49(8):843-8. PubMed ID: 22954018
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Usefulness of omalizumab in ten patients with severe occupational asthma.
    Lavaud F; Bonniaud P; Dalphin JC; Leroyer C; Muller D; Tannous R; Mangiapan G; De Blay F
    Allergy; 2013 Jun; 68(6):813-5. PubMed ID: 23647648
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical and pharmacoeconomic aspects of omalizumab: a 4-year follow-up.
    Menzella F; Facciolongo N; Piro R; Formisano D; Roggeri A; Simonazzi A; Castagnetti C; Carbonelli C; Zucchi L
    Ther Adv Respir Dis; 2012 Apr; 6(2):87-95. PubMed ID: 22323442
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of omalizumab treatment in a baker with occupational asthma.
    Pérez Pimiento A; Bueso Fernández A; García Loria J; Rodríguez Cabreros MI; Mosquera MR; García Cubero A
    J Investig Allergol Clin Immunol; 2008; 18(6):490-1. PubMed ID: 19123449
    [No Abstract]   [Full Text] [Related]  

  • 45. Role of immunmodulators in allergen-specific immunotherapy.
    Kopp MV
    Allergy; 2011 Jun; 66(6):792-7. PubMed ID: 21332502
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effect of omalizumab as add-on therapy on asthma-related quality of life in severe allergic asthma: a Brazilian study (QUALITX).
    Rubin AS; Souza-Machado A; Andradre-Lima M; Ferreira F; Honda A; Matozo TM;
    J Asthma; 2012 Apr; 49(3):288-93. PubMed ID: 22356355
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Successful carboplatin desensitization by using omalizumab and paradoxical diminution of total IgE levels.
    Ojaimi S; Harnett PR; Fulcher DA
    J Allergy Clin Immunol Pract; 2014; 2(1):105-6. PubMed ID: 24565780
    [No Abstract]   [Full Text] [Related]  

  • 48. Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma.
    Massanari M; Nelson H; Casale T; Busse W; Kianifard F; Geba GP; Zeldin RK
    J Allergy Clin Immunol; 2010 Feb; 125(2):383-9. PubMed ID: 20159249
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Omalizumab versus 'usual care': results from a naturalistic longitudinal study in routine care.
    Wittchen HU; Mühlig S; Klotsche J; Buhl R; Kardos P; Ritz T; Riedel O
    Int Arch Allergy Immunol; 2012; 159(1):83-93. PubMed ID: 22573022
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Targeting IgE in asthma.
    Kuhl K; Hanania NA
    Curr Opin Pulm Med; 2012 Jan; 18(1):1-5. PubMed ID: 22139745
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Omalizumab therapy in severe asthma: experience from the Spanish registry--some new approaches.
    Vennera Mdel C; Pérez De Llano L; Bardagí S; Ausin P; Sanjuas C; González H; Gullón JA; Martínez-Moragón E; Carretero JA; Vera E; Medina JF; Alvarez FJ; Entrenas LM; Padilla A; Irigaray R; Picado C;
    J Asthma; 2012 May; 49(4):416-22. PubMed ID: 22443408
    [TBL] [Abstract][Full Text] [Related]  

  • 52. RANTES in exhaled breath condensate of patients with severe persistent allergic asthma during omalizumab therapy.
    Zietkowski Z; Skiepko R; Tomasiak-Lozowska MM; Lenczewska D; Bodzenta-Lukaszyk A
    Int Arch Allergy Immunol; 2011; 154(1):25-32. PubMed ID: 20664274
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Pneumology. Anti-IgE antibodies in the treatment of asthma].
    Leuenberger P; Sauty A; Rochat T
    Rev Med Suisse; 2007 Jan; 3(93):56-9. PubMed ID: 17354662
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of adding omalizumab, an anti-immunoglobulin E antibody, on airway wall thickening in asthma.
    Hoshino M; Ohtawa J
    Respiration; 2012; 83(6):520-8. PubMed ID: 22236804
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Omalizumab as a desensitizing agent and treatment in mastocytosis: a review of the literature and case report.
    Sokol KC; Ghazi A; Kelly BC; Grant JA
    J Allergy Clin Immunol Pract; 2014; 2(3):266-70. PubMed ID: 24811015
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effects of omalizumab in non-atopic asthma: results from a Spanish multicenter registry.
    de Llano LP; Vennera Mdel C; Álvarez FJ; Medina JF; Borderías L; Pellicer C; González H; Gullón JA; Martínez-Moragón E; Sabadell C; Zamarro S; Picado C;
    J Asthma; 2013 Apr; 50(3):296-301. PubMed ID: 23350994
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Safety of omalizumab in asthma.
    Tan RA; Corren J
    Expert Opin Drug Saf; 2011 May; 10(3):463-71. PubMed ID: 21401438
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Total antioxidant capacity, hydrogen peroxide, malondialdehyde and total nitric oxide concentrations in patients with severe persistent allergic asthma: its relation to omalizumab treatment.
    Yalcin AD; Gorczynski RM; Parlak GE; Kargi A; Bisgin A; Sahin E; Kose S; Gumuslu S
    Clin Lab; 2012; 58(1-2):89-96. PubMed ID: 22372350
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cost-effectiveness of omalizumab for uncontrolled allergic asthma in the Netherlands.
    van Nooten F; Stern S; Braunstahl GJ; Thompson C; Groot M; Brown RE
    J Med Econ; 2013; 16(3):342-8. PubMed ID: 23216016
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Omalizumab for the treatment of severe persistent allergic asthma in children aged 6-11 years.
    Walker S; Burch J; McKenna C; Wright K; Griffin S; Woolacott N
    Health Technol Assess; 2011 May; 15 Suppl 1():13-21. PubMed ID: 21609649
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.